Journal
EMERGING INFECTIOUS DISEASES
Volume 12, Issue 1, Pages 66-72Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid1201.051147
Keywords
-
Categories
Funding
- Intramural NIH HHS Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000997, ZIAAI000933, Z01AI000933, Z01AI000997] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Recent outbreaks of highly pathogenic avian influenza in Asia and associated human infections have led to a heightened level of awareness and preparation for a possible influenza pandemic. Vaccination is the best option by which spread of a pandemic virus could be prevented and severity of disease reduced. Production of live attenuated and inactivated vaccine seed viruses against avian influenza viruses, which have the potential to cause pandemics, and their testing in preclinical studies and clinical trials will establish the principles and ensure manufacturing experience that will be critical in the event of the emergence of such a virus into the human population. Studies of such vaccines will also add to our understanding of the biology of avian influenza viruses and their behavior in mammalian hosts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available